These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36854495)

  • 41. Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies.
    Damaskos C; Garmpi A; Nikolettos K; Vavourakis M; Diamantis E; Patsouras A; Farmaki P; Nonni A; Dimitroulis D; Mantas D; Antoniou EA; Nikolettos N; Kontzoglou K; Garmpis N
    Anticancer Res; 2019 Oct; 39(10):5285-5296. PubMed ID: 31570423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Unveiling the antibody-drug conjugates portfolio in battling Triple-negative breast cancer: Therapeutic trends and Future horizon.
    Khadela A; Soni S; Shah AC; Pandya AJ; Megha K; Kothari N; Cb A
    Med Oncol; 2022 Dec; 40(1):25. PubMed ID: 36456774
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Compounds from diverse natural origin against triple-negative breast cancer: A comprehensive review.
    Thilagavathi R; Priyankha S; Kannan M; Prakash M; Selvam C
    Chem Biol Drug Des; 2023 Jan; 101(1):218-243. PubMed ID: 36323650
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer.
    Liao GS; Dai MS; Hsu HM; Chu CH; Hong ZJ; Fu CY; Chou YC; Huang TC; Yu JC
    Eur J Surg Oncol; 2017 Oct; 43(10):1855-1861. PubMed ID: 28756019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol.
    Linciano P; Citti C; Russo F; Tolomeo F; Laganà A; Capriotti AL; Luongo L; Iannotta M; Belardo C; Maione S; Forni F; Vandelli MA; Gigli G; Cannazza G
    Sci Rep; 2020 Dec; 10(1):22019. PubMed ID: 33328530
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.
    McAllister SD; Soroceanu L; Desprez PY
    J Neuroimmune Pharmacol; 2015 Jun; 10(2):255-67. PubMed ID: 25916739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
    J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Racial Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic Factors.
    Prakash O; Hossain F; Danos D; Lassak A; Scribner R; Miele L
    Front Public Health; 2020; 8():576964. PubMed ID: 33415093
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum levels of circulating miRNA-21, miRNA-10b and miRNA-200c in triple-negative breast cancer patients.
    Niedźwiecki S; Piekarski J; Szymańska B; Pawłowska Z; Jeziorski A
    Ginekol Pol; 2018; 89(8):415-420. PubMed ID: 30215459
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Receptor-mediated effects of Δ
    Preteroti MW; Traboulsi H; Greiss P; Lapohos O; Fonseca GJ; Eidelman DH; Baglole CJ
    Immunol Cell Biol; 2023 Feb; 101(2):156-170. PubMed ID: 36510483
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
    Mir MA; Qayoom H; Mehraj U; Nisar S; Bhat B; Wani NA
    Curr Cancer Drug Targets; 2020; 20(8):586-602. PubMed ID: 32418525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted approaches to triple-negative breast cancer: current practice and future directions.
    Brunello A; Borgato L; Basso U; Lumachi F; Zagonel V
    Curr Med Chem; 2013; 20(5):605-12. PubMed ID: 23278396
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
    Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
    Breast J; 2022; 2022():9238804. PubMed ID: 35711896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy.
    Zaib T; Cheng K; Liu T; Mei R; Liu Q; Zhou X; He L; Rashid H; Xie Q; Khan H; Xu Y; Sun P; Wu J
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
    Sheikh UN; Cohen C; Siddiqui MT
    Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship of established risk factors with breast cancer subtypes.
    McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
    Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Triple negative breast cancer: looking for the missing link between biology and treatments.
    Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
    Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.